A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus

Stopped early

Conditions studied: COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE)

In brief

The rapid spread of SARS-CoV-2 (also known as 2019-nCoV and HCoV-19 1), a novel beta coronavirus B lineage (βCoV), has sparked a global coronavirus disease (COVID-19) pandemic. It has been suggested that RRAR, a unique furin-like cleavage site (FCS) in the spike protein (S) that is absent in other B βCoV lines such as SARS-CoV, is responsible for its high infectivity and transmissibility. Furin is a protein with a special function of a fermentative biocatalyst: which recognizes the degree of maturity of a group of amino acids Functionally, Furin works to renew the body, but it is also a path to the introduction of the SARS-CoV virus into a living human cell, HIV virus, Ebola virus, and others that penetrate a human cell using the Furin protein, sending a conditioned signal from the extracellular matrix, and gives the virus the opportunity to merge the protein of the coronavirus spike and the protein content of the cut cell, which activates the phase of virus replication in the body. We hypothesize that measuring the quantitative indicators of Furin protein expression in patients (at the onset of the disease) who have recovered from SARS-CoV-2 and vaccinated (with all types of vaccines) against coronavirus can provide an understanding of the molecular-cellular mechanisms of the virus's cellular invasion. This means that it will be possible to find new ways to prevent the fusion of the membranes of infected cells with normal ones (this mechanism allows the virus to spread throughout the body without leaving the affected cells). Protein identification will be carried out by Enhanced Chemiluminescence (ECL) (the method of enhanced chemiluminescence differs from the method of immunochemical staining using chromogenic substrates by a much greater sensitivity)

Key facts

Study ID

NCT05104840

Run by

Center Trials & Treatment

People needed

2432

Starts

2022-08-10

Expected to finish

2023-03-28

Last updated by the study team

2023-03-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any gender
• Age > 18
• Hospitalized adult male and female patients with Laboratory-confirmed novel coronavirus (SARS-CoV-2) infection
• Laboratory-confirmed novel coronavirus (SARS-CoV-2) infection
• All Confirmed COVID-19 Patients by PCR or highly suspected patients admitted to the chest department's isolation unit during the duration of the study
• Able to understand and provide voluntary informed consent. Informed consent for participation in the study (consent can be oral if written consent cannot be expressed
• Vaccination with any type of SARS-CoV-2 vaccine

You may not qualify if…

• Other medical condition other than COVID-19 or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
• Suspected or known active systemic bacterial, viral (except SARS-CoV2 infection) or fungal infections
• Active herpes zoster infection
• Any physical examination findings and/or history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study
• Participation in other clinical trials of investigational treatments for COVID-19.

Where it is running

• Mayo Clinic-Jacksonville — Jacksonville, Florida, United States
• StatMed Ocala — Ocala, Florida, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• Seattle Intstitute of East Asian Medicine — Seattle, Washington, United States
• Institute of Liver & Biliary Sciences — New Delhi, National Capital Territory of Delhi, India
• Humsafar Trust — Mumbai, India
• Max Super Speciality Hospital Saket — New Delhi, India
• Sher i Kashmir Institute of Medical Sciences — Srinagar, India
• State Institution Republican Clinical Hospital — Kyiv, Ukraine

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.